Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
EXELIXIS, INC. |
Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 21.85 USD | -0.09% | +2.77% | +36.28% | |
Financials (USD)
| Sales 2023 * | 1.84B | Sales 2024 * | 2.07B | Capitalization | 6.8B |
|---|---|---|---|---|---|
| Net income 2023 * | 195M | Net income 2024 * | 283M | EV / Sales 2023 * | 2,57x |
| Net cash position 2023 * | 2.08B | Net cash position 2024 * | 2.43B | EV / Sales 2024 * | 2,11x |
| P/E ratio 2023 * | 35,8x | P/E ratio 2024 * | 23,9x | Employees | 1,223 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 97.98% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -2.50% | ||
| 1 week | +3.90% | ||
| Current month | +0.28% | ||
| 1 month | +4.14% | ||
| 3 months | -1.80% | ||
| 6 months | +12.27% | ||
| Current year | +36.35% |
1 week
21.39
22.44
1 month
20.5622.44
Current year
16.0322.80
1 year
15.3222.80
3 years
14.8725.77
5 years
13.6727.80
10 years
1.2632.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 2000 | |
| Director of Finance/CFO | 55 | 2015 | |
Susan T. Hubbard
IRC | Investor Relations Contact | - | 2016 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alan Garber
BRD | Director/Board Member | 67 | 2004 |
| Director/Board Member | 67 | 2004 | |
George Poste
BRD | Director/Board Member | 78 | 2004 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.24% | 323 M€ | -7.50% | - | |
| 5.01% | 3 M€ | -15.14% | - | |
| 5.01% | 104 M€ | -16.89% | ||
| 3.87% | 1,043 M€ | -6.62% | ||
| 3.87% | 5 M€ | -10.32% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-06 | 21.86 | -0.02% | 754 162 |
| 23-12-05 | 21.87 | -2.50% | 2,075,210 |
| 23-12-04 | 22.43 | +2.23% | 2,032,287 |
| 23-12-01 | 21.94 | +0.60% | 1,854,533 |
| 23-11-30 | 21.81 | +2.54% | 3,140,900 |
Delayed Quote Nasdaq, December 05, 2023 at 04:00 pm EST
More quotes
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has four products, including its flagship molecule, cabozantinib, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Calendar
2024-02-26
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
21.87USD
Average target price
25.75USD
Spread / Average Target
+17.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +36.35% | 6 801 M $ | |
| +13.78% | 87 300 M $ | |
| -7.78% | 31 003 M $ | |
| +23.14% | 27 349 M $ | |
| -34.27% | 23 472 M $ | |
| -25.30% | 20 775 M $ | |
| -16.27% | 19 181 M $ | |
| -0.75% | 11 647 M $ | |
| +24.64% | 11 318 M $ | |
| -31.98% | 8 245 M $ |
